• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
The Rheumatologist's Role in the Battle Against COVID-19: Insights from the Front Line and Challenges for the Future.风湿病学家在抗击新冠疫情中的角色:来自一线的见解与未来挑战
Mediterr J Rheumatol. 2020 Sep 21;31(Suppl 2):247-252. doi: 10.31138/mjr.31.3.247. eCollection 2020 Sep.
2
Management of Patients With Inflammatory Rheumatic Diseases: Telemedicine and Rheumatologists Challenged in the Era of COVID-19.炎症性风湿疾病患者的管理:远程医疗与风湿科医生在新冠疫情时代面临的挑战
Front Public Health. 2020 Nov 9;8:558838. doi: 10.3389/fpubh.2020.558838. eCollection 2020.
3
Impact of SARS-CoV-2/COVID-19 on Provision of Medical Care to Patients With Systemic Autoimmune Rheumatic Disease and the Practice of Rheumatology.严重急性呼吸综合征冠状病毒2型/冠状病毒病2019对系统性自身免疫性风湿病患者医疗服务提供及风湿病诊疗实践的影响
Cureus. 2023 Feb 24;15(2):e35402. doi: 10.7759/cureus.35402. eCollection 2023 Feb.
4
Impact of Chronic Use of Antimalarials on SARS-CoV-2 Infection in Patients With Immune-Mediated Rheumatic Diseases: Protocol for a Multicentric Observational Cohort Study.长期使用抗疟药对免疫介导的风湿性疾病患者感染严重急性呼吸综合征冠状病毒2的影响:一项多中心观察性队列研究方案
JMIR Res Protoc. 2020 Oct 14;9(10):e23532. doi: 10.2196/23532.
5
COVID-19 Associated Ischemic Stroke and Hemorrhagic Stroke: Incidence, Potential Pathological Mechanism, and Management.新型冠状病毒肺炎相关缺血性卒中和出血性卒中:发病率、潜在病理机制及管理
Front Neurol. 2020 Oct 27;11:571996. doi: 10.3389/fneur.2020.571996. eCollection 2020.
6
Molecular Insights Into SARS COV-2 Interaction With Cardiovascular Disease: Role of RAAS and MAPK Signaling.SARS-CoV-2与心血管疾病相互作用的分子见解:肾素-血管紧张素-醛固酮系统(RAAS)和丝裂原活化蛋白激酶(MAPK)信号传导的作用
Front Pharmacol. 2020 Jun 3;11:836. doi: 10.3389/fphar.2020.00836. eCollection 2020.
7
Identification of novel mutations in the methyltransferase complex (Nsp10-Nsp16) of SARS-CoV-2.新型冠状病毒(SARS-CoV-2)甲基转移酶复合物(Nsp10-Nsp16)中新型突变的鉴定
Biochem Biophys Rep. 2020 Dec;24:100833. doi: 10.1016/j.bbrep.2020.100833. Epub 2020 Oct 10.
8
Eligibility of rheumatoid arthritis patients for anti-TNF-alpha therapy according to the 2005 recommendations of the French and British Societies for Rheumatology.根据法国和英国风湿病学会2005年的建议,类风湿关节炎患者接受抗TNF-α治疗的资格。
Rheumatology (Oxford). 2008 Nov;47(11):1698-703. doi: 10.1093/rheumatology/ken348. Epub 2008 Sep 15.
9
Cognitive and Neuropsychiatric Manifestations of COVID-19 and Effects on Elderly Individuals With Dementia.新型冠状病毒肺炎的认知和神经精神表现及其对老年痴呆症患者的影响
Front Aging Neurosci. 2020 Oct 26;12:588872. doi: 10.3389/fnagi.2020.588872. eCollection 2020.
10
Identifying rheumatic disease patients at high risk and requiring shielding during the COVID-19 pandemic.识别在新冠疫情期间处于高风险且需要防护的风湿性疾病患者。
Clin Med (Lond). 2020 May 15;20(3):256-261. doi: 10.7861/clinmed.2020-0149. Print 2020 May 5.

引用本文的文献

1
Impact of SARS-CoV-2/COVID-19 on Provision of Medical Care to Patients With Systemic Autoimmune Rheumatic Disease and the Practice of Rheumatology.严重急性呼吸综合征冠状病毒2型/冠状病毒病2019对系统性自身免疫性风湿病患者医疗服务提供及风湿病诊疗实践的影响
Cureus. 2023 Feb 24;15(2):e35402. doi: 10.7759/cureus.35402. eCollection 2023 Feb.

本文引用的文献

1
Anakinra for severe forms of COVID-19: a cohort study.阿那白滞素用于重症新型冠状病毒肺炎:一项队列研究。
Lancet Rheumatol. 2020 Jul;2(7):e393-e400. doi: 10.1016/S2665-9913(20)30164-8. Epub 2020 May 29.
2
Could severe COVID-19 be considered a complementopathy?重症新型冠状病毒肺炎能否被视为一种补体病?
Lupus Sci Med. 2020 May;7(1). doi: 10.1136/lupus-2020-000415.
3
Tocilizumab for Treatment of Severe COVID-19 Patients: Preliminary Results from SMAtteo COvid19 REgistry (SMACORE).托珠单抗治疗重症COVID-19患者:来自SMAtteo COvid19 REgistry(SMACORE)的初步结果
Microorganisms. 2020 May 9;8(5):695. doi: 10.3390/microorganisms8050695.
4
Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy.托珠单抗治疗伴有炎症过度反应和急性呼吸衰竭的重症 COVID-19 肺炎:意大利布雷西亚单中心 100 例患者研究。
Autoimmun Rev. 2020 Jul;19(7):102568. doi: 10.1016/j.autrev.2020.102568. Epub 2020 May 3.
5
Effective treatment of severe COVID-19 patients with tocilizumab.托珠单抗治疗重症 COVID-19 患者有效。
Proc Natl Acad Sci U S A. 2020 May 19;117(20):10970-10975. doi: 10.1073/pnas.2005615117. Epub 2020 Apr 29.
6
What is the true incidence of COVID-19 in patients with rheumatic diseases?风湿性疾病患者中新型冠状病毒肺炎的真实发病率是多少?
Ann Rheum Dis. 2021 Feb;80(2):e18. doi: 10.1136/annrheumdis-2020-217615. Epub 2020 Apr 22.
7
COVID-19 and rheumatology: first steps towards a different future?新型冠状病毒肺炎与风湿病学:迈向不同未来的第一步?
Ann Rheum Dis. 2020 May;79(5):551-552. doi: 10.1136/annrheumdis-2020-217494.
8
Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19.新型冠状病毒肺炎患者的凝血障碍与抗磷脂抗体
N Engl J Med. 2020 Apr 23;382(17):e38. doi: 10.1056/NEJMc2007575. Epub 2020 Apr 8.
9
Understanding and Addressing Sources of Anxiety Among Health Care Professionals During the COVID-19 Pandemic.了解并应对新冠疫情期间医护人员的焦虑源
JAMA. 2020 Jun 2;323(21):2133-2134. doi: 10.1001/jama.2020.5893.
10
What is the role of rheumatologists in the era of COVID-19?在新冠疫情时代,风湿病学家的作用是什么?
Autoimmun Rev. 2020 Jun;19(6):102539. doi: 10.1016/j.autrev.2020.102539. Epub 2020 Apr 3.

风湿病学家在抗击新冠疫情中的角色:来自一线的见解与未来挑战

The Rheumatologist's Role in the Battle Against COVID-19: Insights from the Front Line and Challenges for the Future.

作者信息

Koutsianas Christos, Chatzidionysiou Katerina

机构信息

Department of Rheumatology, The Dudley Group NHS Foundation Trust, Dudley, West Midlands, United Kingdom.

Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Solna, Karolinska Institute, Stockholm, Sweden.

出版信息

Mediterr J Rheumatol. 2020 Sep 21;31(Suppl 2):247-252. doi: 10.31138/mjr.31.3.247. eCollection 2020 Sep.

DOI:10.31138/mjr.31.3.247
PMID:33196000
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7656125/
Abstract

As the worldwide burden of COVID-19 increases exponentially, healthcare systems are plagued by unprecedented pressure. In this setting, many rheumatologists across the globe have been recruited to support the front line, facing several unexpected challenges, but also providing valuable skills in combating COVID-19. At the same time, the rheumatic disease patient population may be especially vulnerable to such a rapidly contagious infectious disease and thus needs care and support that has to be provided quickly and efficiently. Clear advice on viral spread mitigation, precise guidelines on immunosuppressive treatment use and alternative methods of providing care, such as telemedicine, are a few of the rheumatologists' new challenges in caring for their patients in the COVID-19 era. Finally, among other specialties, rheumatologists hold a unique place in the fight against the hyper-inflammatory state caused by severe SARS-CoV-2 infection, leading to increased morbidity and mortality. Given their vast experience in the use of biologic and targeted therapies, rheumatologists should lead the way in developing reliable scientific evidence for the optimal treatment of severe COVID-19.

摘要

随着新冠疫情在全球的负担呈指数级增长,医疗系统正面临前所未有的压力。在这种情况下,全球许多风湿病学家被招募来支援前线,他们面临着一些意想不到的挑战,但也在抗击新冠疫情中发挥了宝贵作用。与此同时,风湿病患者群体可能特别容易受到这种快速传播的传染病的影响,因此需要迅速而有效地提供护理和支持。关于减轻病毒传播的明确建议、免疫抑制治疗使用的精确指南以及提供护理的替代方法,如远程医疗,是风湿病学家在新冠疫情时代照顾患者时面临的一些新挑战。最后,在其他专科中,风湿病学家在对抗由严重SARS-CoV-2感染引起的过度炎症状态方面占据独特地位,这种状态会导致发病率和死亡率上升。鉴于他们在使用生物制剂和靶向治疗方面的丰富经验,风湿病学家应率先为重症新冠疫情的最佳治疗提供可靠的科学依据。